NSCLC患者基因突变与其临床病理特征的相关性  

Relationship of gene mutations and clinicopathologic features in patients with non-small cell lung cancer

作　　者：董跃华[1] 王贵刚[1] 杨燕君[1] 魏玉磊[1] 高永山[1] 姜伟华[1] DONG Yuehua;WANG Guigang;YANG Yanjun;WEI Yulei;GAO Yongshan;JIANG Weihua(Department of Cardiothoracicsurgery,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,Hebei,China)

机构地区：[1]河北北方学院附属第一医院胸心外科,河北张家口075000

出　　处：《西部医学》2022年第4期493-497,共5页Medical Journal of West China

基　　金：河北省2017年度医学科学研究重点课题计划(20170779)。

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)、Runx3和间质上皮转化因子(Met)突变与其病理分型、TNM分期及生存期的相关性。方法收集2014年2月~2016年8月我院经手术途径留取新鲜肿瘤标本96例。对新鲜肿瘤样本采用免疫组化法检测EGFR、Runx3和Met表达,并通过二代测序技术(NGS)检测组织样本中EGFR、Runx3和Met基因突变情况。生存期随访时间从病例确诊至2019年12月31日。研究NSCLC患者EGFR、Runx3和Met表达、突变情况与其病理分型、TNM分期及生存期的相关性。结果Runx3表达与分期、复发转移有关(P<0.05);Met表达与分期、组织学分型有关(P<0.05)。EGFR突变与组织学分型、生存时间有关(P<0.05);Runx3突变与患者组织学分型、分期、复发转移、生存时间有关(P<0.05);EGFR、Runx3突变均与患者生存时间呈正相关(P<0.05);Runx3的表达及突变与患者复发转移呈正相关(P<0.05);Met突变情况与患者组织学分型、分期、复发转移、生存时间、病理分化均无相关性(P>0.05)。结论EGFR突变可与Runx3、Met突变共存,Met突变率较低。EGFR与Runx3的突变有望成为NSCLC患者组织学分型、判断预后的潜在指标,为实施精准治疗提供理论支撑。Objective To explore the mutations of EGFR,Runx3,Met in non-small-cell lung carcinoma patients and their correlation with pathological classification,TNM stage and survival period.Methods A total of 96 fresh tumor specimens were collected from June 2014 to February 2016 through surgical procedures.The expressions of EGFR,Runx3 and Met were detected by immunohistochemistry,and the mutations of EGFR,Runx3 and Met genes in tissue samples were detected by next generation sequencing(NGS)to study the correlation of EGFR,Runx3 and Met expression,mutation status with pathological classification,TNM stage and survival period in NSCLC patients.The patients were follow-up by telephone or outpatient service.The follow-up time will be from the diagnosis of the case to December 31,2019.Results Runx3 expression was related to TNM stage,recurrence and Metastasis(P<0.05).Met expression was related to stage and histological typing(P<0.05).EGFR mutation is related to patient’s gender,smoking history,histological classification and survival time(P<0.05).Runx3 mutation was related to patient age,histological classification,stage,recurrence and metastasis,survival time(P<0.05).The EGFR and Runx3 mutation have the positive correlation with the survival time.The expression and mutation of Runx3 have the positive correlation with the recurrence and metastasis.In contrast,the patient’s age,gender,smoking history,histological classification,stage,recurrence and metastasis,survival time,and pathological differentiation were not related to the Met mutation(P>0.05).Conclusion EGFR mutations can coexist with Runx3 and Met mutations,and the Met mutation rate is low.The mutations of EGFR and Runx3 are expected to become potential indicators for histological typing and prognosis of NSCLC patients,and provide theoretical support for the implementation of precise treatment.

关 键 词：非小细胞肺癌 表皮生长因子受体 RUNX3基因 间质上皮转化因子 生存时间 

分 类 号：R734.2[医药卫生—肿瘤]